Stevanato Group (STVN)
(Delayed Data from NYSE)
$27.54 USD
+0.02 (0.07%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.50 -0.04 (-0.15%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.54 USD
+0.02 (0.07%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.50 -0.04 (-0.15%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Zacks News
Stevanato Group (STVN) to Report Q1 Results: What You Should Expect
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TAK or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TAK vs. STVN: Which Stock Is the Better Value Option?
Stevanato Group (STVN) Q3 Earnings Meet Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 0% and 3.22%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
TAK vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
TAK vs. STVN: Which Stock Is the Better Value Option?
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
USNA or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
USNA vs. STVN: Which Stock Is the Better Value Option?
GRFS or STVN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. STVN: Which Stock Is the Better Value Option?
All You Need to Know About Stevanato (STVN) Rating Upgrade to Buy
by Zacks Equity Research
Stevanato (STVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stevanato Group (STVN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 7.14% and 0.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Stevanato (STVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Stevanato Group (STVN) Q1 Earnings Lag Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of -7.69% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato Group S.p.A. (STVN) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Hold Teladoc Health (TDOC) Stock Now
by Zacks Equity Research
Teladoc Health (TDOC) remains well-poised for growth on the back of solid revenues, sustained demand for virtual care services and sufficient cash-generating abilities.
Stevanato Group S.p.A. (STVN) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Stevanato (STVN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Surging Earnings Estimates Signal Upside for Stevanato (STVN) Stock
by Zacks Equity Research
Stevanato (STVN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 18.75% and 9.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Matches Q4 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of 0% and 1.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -106.67% and 79.49%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 7.69% and 0.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ASRT vs. STVN: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. STVN: Which Stock Is the Better Value Option?
ASRT vs. STVN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. STVN: Which Stock Is the Better Value Option?
Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Stevanato (STVN) delivered earnings and revenue surprises of 8.33% and 5.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?